Bristol Myers Squibb (NYSE: BMY; BMS) beat analyst consensus forecasts by reporting higher than expected numbers for total revenue and its “growth” portfolio of drugs on which BMS is counting on for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results